About us > Board
Non-executive Chairman – Dr Steven Powell
Steven is Chief Executive Officer of Plethora Solutions plc. Prior to this he was a Director at Gilde Investment Management, and retains responsibility for Gilde’s UK portfolio companies. He joined Gilde from KS Biomedix plc, where he was CEO from 1999 until its acquisition by Xenova in 2003. He has worked in the pharmaceutical and biotechnology industry since 1985, initially with Beecham Pharmaceuticals (now GSK) as a development scientist and subsequently with Whatman, Radiometer, Chiroscience and Active Biotech.
CEO – Dr Julian Gilbert
Previously Julian was Co-founder and Commercial Director of Arakis, a low risk discovery and development company. Arakis raised £49m in private equity and developed a pipeline of five clinical phase opportunities. Its most advanced product opportunities were out-licensed to Novartis (AD 237 for COPD) and Mundipharma (AD 923 for cancer breakthrough pain). Arakis was sold to Sosei in 2005 for £106m. Julian has worked in the industry for more than 20 years and gained broad commercial and technical experience at SmithKline & French, BTG, Mundipharma and Chiroscience.
Non-executive Director – Pieter van der Meer
Pieter is General Partner in the Healthcare venture fund at Gilde, where he has had a focus on early stage investments in pharmaceutical and biotechnology based companies. Pieter joined Gilde in 1998 after several years working with KPMG Management Consulting where he led due diligence projects in the pharmaceutical sector. Pieter holds an MSc in Chemistry from Leiden University where he specialized in bio-organic synthesis and molecular modelling and also holds a degree in Commercial Economics. Mr van der Meer led investments in Ablynx, Agendia, Inpharmatica and BG Medicine. He represented Gilde on the board of Ablynx and is currently on the boards of Acacia Pharma, Agendia and BG Medicine.